Local Administration of HTX-011, a Long-Acting Biochronomer®-Based Bupivacaine/Meloxicam Combination, in Hernia Repair: Preliminary Results of an Interim Analysis

Authors: Peter Winkle, Harold S. Minskowitz, Etel Onel, Guy Baccin, Alice Chi, Neil J. Chandy, Mary Rose Keller, Thomas Otoboni, Sandip Patel, 1 Barry Quan 1

Affiliations: Ansell® Regional Medical Center, Anaheim, CA; Ansell, CA; Memorial Hermann Memorial City Medical Center, Houston, TX; Herase Therapeutics, Inc, San Diego, CA.

BACKGROUND

- Phase 2 trial investigating PK - Clinical laboratory
- Following the administration of HTX-011, Lynch, Ottoboni, Short
- Baseline demographics

METHODS

- Subjects and Disposition
- Efficacy of HTX-011

RESULTS

- Table 1: Baseline Demographic and Baseline Pain Scores After HTX-011
- Table 2: Summary of Treatment Emergent Adverse Events (TEAEs)

CONCLUSIONS

- HTX-011 is a novel, long-acting, and durable pain control for emergent and elective hernia repair.
- The efficacy of HTX-011 was demonstrated through 14 days posttreatment.

REFERENCES

- 4. Onel, 2016;157:1259

SAFETY OF HTX-011

- HTX-011 is a novel, long-acting, and durable pain control for emergent and elective hernia repair.
- The safety of HTX-011 was demonstrated through 14 days posttreatment.

PHARMACOKINETICS OF HTX-011B

- Table 1: Summary of Plasma Concentration-Time Profiles of Bupivacaine and Meloxicam

TABLE 1: SUMMARY OF PLASMA CONCENTRATION-TIME PROFILES OF BUPIVACAINE AND MELOXICAM

- 4. Onel, 2016;157:1259

CONCLUSIONS

- HTX-011 is a novel, long-acting, and durable pain control for emergent and elective hernia repair.
- The efficacy of HTX-011 was demonstrated through 14 days posttreatment.

REFERENCES

- 4. Onel, 2016;157:1259